Abstract
In Staphylococcus aureus infections in men eligible for doxycycline post-exposure prophylaxis (doxy-PEP), tetracycline non-susceptibility is more prevalent than in the overall population and is associated with resistance to trimethoprim-sulfamethoxazole and clindamycin. Doxy-PEP may select for S. aureus multi-drug resistance, underscoring the importance of surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project described was supported by Grant Number T32 AI007433 from the National Institute of Allergy and Infectious Diseases. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This project was funded in part by contract 200-2016-91779 with the Centers for Disease Control (CDC) and Prevention. Disclaimer: The findings, conclusions, and views expressed are those of the authors and do not necessarily represent the official position of the CDC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Massachusetts General Brigham gave ethical approval for this work (Protocol # 2003P000336).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in the present study is protected health information and therefore not publicly available. Upon request to the authors, a de-identified sample dataset can be provided.
